Optimization of doses received by the hospital staff and the members of the family of patients undergoing 111In-DTPA-D-Phe1-Octreotide therapy.
Identifieur interne : 002612 ( Main/Exploration ); précédent : 002611; suivant : 002613Optimization of doses received by the hospital staff and the members of the family of patients undergoing 111In-DTPA-D-Phe1-Octreotide therapy.
Auteurs : RBID : pubmed:17223636Descripteurs français
- Wicri :
- geographic : Grèce.
English descriptors
- KwdEn :
- Equipment Design, Equipment Failure Analysis, Family, Greece, Internationality, Medical Staff, Occupational Exposure (analysis), Pentetic Acid (analogs & derivatives), Pentetic Acid (analysis), Pentetic Acid (therapeutic use), Radiation Dosage, Radiation Monitoring (methods), Radiation Protection (methods), Radiopharmaceuticals (analysis), Radiopharmaceuticals (therapeutic use), Reproducibility of Results, Sensitivity and Specificity.
- MESH :
- chemical , analogs & derivatives : Pentetic Acid.
- chemical , analysis : Pentetic Acid, Radiopharmaceuticals.
- chemical , therapeutic use : Pentetic Acid, Radiopharmaceuticals.
- geographic : Greece.
- analysis : Occupational Exposure.
- methods : Radiation Monitoring, Radiation Protection.
- Equipment Design, Equipment Failure Analysis, Family, Internationality, Medical Staff, Radiation Dosage, Reproducibility of Results, Sensitivity and Specificity.
Abstract
According to the Euratom Directives (96/29, 97/43), the doses received by the workers as well as the family of patients and third persons during medical exposures, should conform to the dose constraint levels (DCLs), established by the authorities for each group in the context of optimisation. This study deals with the implementation of a radiation protection protocol, concerning the aforementioned group members for patients undergoing treatment with 111In-DTPA-D-Phe1-Octreotide, after intra-arterial infusion. It is shown that by applying this protocol the annual doses to the medical and technical staff are considerably reduced and remain below the established DCLs. Following the post-release behaviour instructions given to the patient, doses to the family and third persons may be kept lower than the corresponding DCLs provided by the National Regulations.
DOI: 10.1093/rpd/ncl563
PubMed: 17223636
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimization of doses received by the hospital staff and the members of the family of patients undergoing 111In-DTPA-D-Phe1-Octreotide therapy.</title><author><name sortKey="Kontogeorgakos, D" uniqKey="Kontogeorgakos D">D Kontogeorgakos</name><affiliation wicri:level="1"><nlm:affiliation>Nuclear Medicine Division, Radiology Department, Aretaieion University Hospital, Vas. Sophias Avenue 76, 11528 Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Nuclear Medicine Division, Radiology Department, Aretaieion University Hospital, Vas. Sophias Avenue 76, 11528 Athens</wicri:regionArea></affiliation></author><author><name sortKey="Limouris, G S" uniqKey="Limouris G">G S Limouris</name></author><author><name sortKey="Kamenopoulou, V" uniqKey="Kamenopoulou V">V Kamenopoulou</name></author><author><name sortKey="Carinou, E" uniqKey="Carinou E">E Carinou</name></author><author><name sortKey="Papanikolos, G" uniqKey="Papanikolos G">G Papanikolos</name></author><author><name sortKey="Vlahos, L" uniqKey="Vlahos L">L Vlahos</name></author><author><name sortKey="Dimitriou, P" uniqKey="Dimitriou P">P Dimitriou</name></author></titleStmt><publicationStmt><date when="2007">2007</date><idno type="doi">10.1093/rpd/ncl563</idno><idno type="RBID">pubmed:17223636</idno><idno type="pmid">17223636</idno><idno type="wicri:Area/Main/Corpus">002916</idno><idno type="wicri:Area/Main/Curation">002916</idno><idno type="wicri:Area/Main/Exploration">002612</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Equipment Design</term><term>Equipment Failure Analysis</term><term>Family</term><term>Greece</term><term>Internationality</term><term>Medical Staff</term><term>Occupational Exposure (analysis)</term><term>Pentetic Acid (analogs & derivatives)</term><term>Pentetic Acid (analysis)</term><term>Pentetic Acid (therapeutic use)</term><term>Radiation Dosage</term><term>Radiation Monitoring (methods)</term><term>Radiation Protection (methods)</term><term>Radiopharmaceuticals (analysis)</term><term>Radiopharmaceuticals (therapeutic use)</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Pentetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Pentetic Acid</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Pentetic Acid</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Greece</term></keywords><keywords scheme="MESH" qualifier="analysis" xml:lang="en"><term>Occupational Exposure</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiation Monitoring</term><term>Radiation Protection</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Equipment Design</term><term>Equipment Failure Analysis</term><term>Family</term><term>Internationality</term><term>Medical Staff</term><term>Radiation Dosage</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Grèce</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">According to the Euratom Directives (96/29, 97/43), the doses received by the workers as well as the family of patients and third persons during medical exposures, should conform to the dose constraint levels (DCLs), established by the authorities for each group in the context of optimisation. This study deals with the implementation of a radiation protection protocol, concerning the aforementioned group members for patients undergoing treatment with 111In-DTPA-D-Phe1-Octreotide, after intra-arterial infusion. It is shown that by applying this protocol the annual doses to the medical and technical staff are considerably reduced and remain below the established DCLs. Following the post-release behaviour instructions given to the patient, doses to the family and third persons may be kept lower than the corresponding DCLs provided by the National Regulations.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17223636</PMID><DateCreated><Year>2008</Year><Month>03</Month><Day>12</Day></DateCreated><DateCompleted><Year>2008</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0144-8420</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>1-4</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Radiation protection dosimetry</Title><ISOAbbreviation>Radiat Prot Dosimetry</ISOAbbreviation></Journal><ArticleTitle>Optimization of doses received by the hospital staff and the members of the family of patients undergoing 111In-DTPA-D-Phe1-Octreotide therapy.</ArticleTitle><Pagination><MedlinePgn>403-6</MedlinePgn></Pagination><Abstract><AbstractText>According to the Euratom Directives (96/29, 97/43), the doses received by the workers as well as the family of patients and third persons during medical exposures, should conform to the dose constraint levels (DCLs), established by the authorities for each group in the context of optimisation. This study deals with the implementation of a radiation protection protocol, concerning the aforementioned group members for patients undergoing treatment with 111In-DTPA-D-Phe1-Octreotide, after intra-arterial infusion. It is shown that by applying this protocol the annual doses to the medical and technical staff are considerably reduced and remain below the established DCLs. Following the post-release behaviour instructions given to the patient, doses to the family and third persons may be kept lower than the corresponding DCLs provided by the National Regulations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kontogeorgakos</LastName><ForeName>D</ForeName><Initials>D</Initials><Affiliation>Nuclear Medicine Division, Radiology Department, Aretaieion University Hospital, Vas. Sophias Avenue 76, 11528 Athens, Greece.</Affiliation></Author><Author ValidYN="Y"><LastName>Limouris</LastName><ForeName>G S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Kamenopoulou</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Carinou</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Papanikolos</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Vlahos</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dimitriou</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Radiat Prot Dosimetry</MedlineTA><NlmUniqueID>8109958</NlmUniqueID><ISSNLinking>0144-8420</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>(111)indium-DTPA-D-phe octreoide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Equipment Failure Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic">Greece</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Medical Staff</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Occupational Exposure</DescriptorName><QualifierName MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">analysis</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiation Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiation Monitoring</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiation Protection</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">analysis</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2007</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">ncl563</ArticleId><ArticleId IdType="doi">10.1093/rpd/ncl563</ArticleId><ArticleId IdType="pubmed">17223636</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002612 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002612 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17223636
|texte= Optimization of doses received by the hospital staff and the members of the family of patients undergoing 111In-DTPA-D-Phe1-Octreotide therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17223636" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |